These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 18679382)

  • 1. Bioabsorbable drug-eluting stents: the future of coronary angioplasty?
    Macaya C; Moreno R
    Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):598-9. PubMed ID: 18679382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
    Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B
    Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial.
    Onuma Y; Serruys PW; Ormiston JA; Regar E; Webster M; Thuesen L; Dudek D; Veldhof S; Rapoza R
    EuroIntervention; 2010 Sep; 6(4):447-53. PubMed ID: 20884431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus-eluting bioabsorbable stent--Abbot Vascular programme.
    Onuma Y; Piazza N; Ormiston JA; Serruys PW
    EuroIntervention; 2009 Dec; 5 Suppl F():F98-F102. PubMed ID: 22100687
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials.
    Tanimoto S; Serruys PW; Thuesen L; Dudek D; de Bruyne B; Chevalier B; Ormiston JA
    Catheter Cardiovasc Interv; 2007 Oct; 70(4):515-23. PubMed ID: 17503509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the drug-eluting stent trials.
    Coolong A; Kuntz RE
    Am J Cardiol; 2007 Sep; 100(5A):17K-24K. PubMed ID: 17719349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflation time and drug-eluting stent: the longer, the better..
    Bertrand OF
    Catheter Cardiovasc Interv; 2009 Feb; 73(2):212-3. PubMed ID: 19156881
    [No Abstract]   [Full Text] [Related]  

  • 10. The long-term results of the "Endeavor" stent.
    Kornovski R
    Catheter Cardiovasc Interv; 2009 Dec; 74(7):996-9. PubMed ID: 19953512
    [No Abstract]   [Full Text] [Related]  

  • 11. Assimilating the current clinical data of fully bioabsorbable stents.
    Di Mario C; Borgia F
    EuroIntervention; 2009 Dec; 5 Suppl F():F103-8. PubMed ID: 22100669
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes.
    Serruys PW; Onuma Y; Dudek D; Smits PC; Koolen J; Chevalier B; de Bruyne B; Thuesen L; McClean D; van Geuns RJ; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Sudhir K; Garcia-Garcia HM; Ormiston JA
    J Am Coll Cardiol; 2011 Oct; 58(15):1578-88. PubMed ID: 21958884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized clinical trials.
    Piscione F; Piccolo R; Cassese S; Galasso G; Chiariello M
    Catheter Cardiovasc Interv; 2009 Aug; 74(2):323-32. PubMed ID: 19360858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease.
    Nikolsky E; Lansky AJ; Sudhir K; Doostzadeh J; Cutlip DE; Piana R; Su X; White R; Simonton CA; Stone GW
    Am Heart J; 2009 Oct; 158(4):520-526.e2. PubMed ID: 19781409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents.
    Gomez-Lara J; Garcia-Garcia HM; Onuma Y; Garg S; Regar E; De Bruyne B; Windecker S; McClean D; Thuesen L; Dudek D; Koolen J; Whitbourn R; Smits PC; Chevalier B; Dorange C; Veldhof S; Morel MA; de Vries T; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2010 Nov; 3(11):1190-8. PubMed ID: 21087756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring in vivo absorption of a drug-eluting bioabsorbable stent with intravascular ultrasound-derived parameters a feasibility study.
    Bruining N; de Winter S; Roelandt JR; Regar E; Heller I; van Domburg RT; Hamers R; Onuma Y; Dudek D; Webster MW; Thuesen L; Ormiston JA; Cheong WF; Miquel-Hebert K; Veldhof S; Serruys PW
    JACC Cardiovasc Interv; 2010 Apr; 3(4):449-56. PubMed ID: 20398874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel paclitaxel-eluting dedicated bifurcation stent: a case report from the first human use Taxus Petal trial.
    Johnson TW; Kay IP; Ormiston JA
    Catheter Cardiovasc Interv; 2009 Apr; 73(5):637-40. PubMed ID: 19213074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus for stent-based intracoronary applications.
    Grube E; Buellesfeld L
    Rev Cardiovasc Med; 2004; 5 Suppl 2():S3-8. PubMed ID: 15184828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.